Absci (ABSI) vs. The Competition Critical Contrast

Absci (NASDAQ:ABSI – Get Rating) is one of 39 public companies in the “Commercial physical research” industry, but how does it contrast to its competitors? We will compare Absci to similar companies based on the strength of its valuation, analyst recommendations, institutional ownership, earnings, risk, dividends and profitability.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Absci and its competitors, as provided by MarketBeat.com.

sell ratings hold ratings Buy rating Strong Buy Ratings rating score
absci 1 3 3 0 2.29
Absci Competitors 105 766 1304 30 2.57

Absci presently has a consensus price target of $24.00, suggesting a potential upside of 593.64%. As a group, “Commercial physical research” companies have a potential upside of 49.93%. Given Absci’s higher probable upside, analysts plainly believe Absci is more favorable than its competitors.

Institutional and Insider Ownership

40.0% of Absci shares are owned by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 11.4% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Absci and its competitors revenue, earnings per share and valuation.

Gross revenue Net Income Price/earnings ratio
absci $4.78 million -$100.96 million -1.04
Absci Competitors $2.80 billion $101.15 million 13.24

Absci’s competitors have higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Absci and its competitors’ net margins, return on equity and return on assets.

net margins return on equity return on assets
absci -2,633.14% -36.19% -22.99%
Absci Competitors -260.35% -8.17% -2.92%


Absci competitors beat Absci on 11 of the 12 factors compared.

About Absci (Get Rating)

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Receive News & Ratings for Absci Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Absci and related companies with MarketBeat.com’s FREE daily email newsletter.